The global progressive supranuclear palsy (PSP) market, valued at USD 231 million in 2025, is projected to reach USD 313 million in 2026 and USD 492 million by 2030, with a 11.9% CAGR during the forecast period, 2026 to 2030. One of the key objectives of the report was to estimate the existing market size and the future opportunity of therapies for Progressive Supranuclear Palsy, over the next decade. Based on multiple parameters, such as disease prevalence, anticipated adoption of the forecaste...

This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elements, the study includes detailed assessment of the current market landscape, providing information about the product

This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elements, the study includes detailed assessment of the current market landscape, providing information about the product

The clinical trial design market is estimated to be worth $441 million in 2021 and is expected to grow at CAGR of 8% during the forecast period. Clinical trials form an integral part of the overall drug development process, as they enable both innovators and regulators to assess the safety and efficacy of a drug candidate. The critical role of these studies can also be verified from the fact that they capture around 50% share of the total time and cost related investments made for the developmen...

Bevacizumab is VEGF-A targeting, humanized monoclonal antibody-based therapeutic developed by Genentech and Roche. It was the first angiogenesis inhibitor drug to be approved by the US FDA. Avastin

This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elements, the study includes detailed assessment of the current market landscape, providing information about the product

Chronic diseases, such as diabetes, arthritis, hypertension and cancer, are considered among the leading causes of death, worldwide. Lack of adherence to prescribed medication regimens (due to various reasons) and high cost of treatment (a significant share of which stems from non-compliance to treatment), are the major contributing factors to the associated burden on patients and the healthcare system. However, modern therapy administration technology, such as wearable and implantable drug deli...

TThis report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elements, the study includes detailed assessment of the current market landscape, providing information about the product

This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elements, the study includes detailed assessment of the current market landscape, providing information about the product

The HER2 receptor is a well characterized biomarker that is overexpressed in a number of types of cancer cells, including 25% to 30% of breast cancers. It was discovered and developed by scientists at Genentech (a fully own subsidiary of Roche), in collaboration with the University of California, Los Angeles; the first clinical trial of the drug was initiated in 1992. Moreover, in combination with certain other chemotherapies (such as paclitaxel), the drug has been shown to significantly improve...

This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elements, the study includes detailed assessment of the current market landscape, providing information about the product

The global RNA targeted therapeutics market size, valued at USD 1,764 million in 2025, is projected to reach USD 2,245 million in 2026 and USD 8,276 million by 2030, representing a CAGR of 38.6% during the forecast period. In recent past, RNA’s limitless potential as a target for small molecules, against a wide range of indications (both oncological and non-oncological), has been recognized. Specifically, a variety of small molecules that affect RNA function have been discovered. Further, many...

This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elements, the study includes detailed assessment of the current market landscape, providing information about the product

This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elements, the study includes detailed assessment of the current market landscape, providing information about the product

This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elements, the study includes detailed assessment of the current market landscape, providing information about the product

This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elements, the study includes detailed assessment of the current market landscape, providing information about the product

The “Industrial Internet of Things (IIOT) Thermal Monitoring Solutions Market: Global Trend and Opportunity Analysis, 2021-2031” report features an extensive study of the current market landscape of players engaged in this upcoming industry.